Leading the Way in Life Science Technologies

GEN Exclusives

More »

Insight & Intelligence™

Back to Item »

Ocrelizumab: One Size Does Not Fit All

Risk of serious infections has hampered mAb’s development in RA and LE, but drug is still being tested in MS.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »